Encarnacion Sastre nackt sorted by
relevance

Admin30.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Encarnacion nackt Sastre Encarnación Sastre
This study was designed to explore the role of circulating tumour cell CTC count as a biomarker to select patients for therapy with FOLFOXIRI-bevacizumab.
shoes
5506
Admin25.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Encarnacion nackt Sastre FOLFOXIRI plus
7 with FOLFOX-bevacizumab stratified HR, 0.
oral
801
Admin10.06.2021

Encarnación Sastre

Encarnacion nackt Sastre Encarnación Sastre
split " " ; if -1! CTC, circulating tumour cell; ECOG, Eastern Cooperative Oncology Group; FOLFOX, 5-fluorouracil, leucovorin and oxaliplatin; FOLFOXIRI, 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.
beach
89010
Admin11.08.2021

Encarnación Sastre

Encarnacion nackt Sastre FOLFOXIRI plus
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
high-heels
4005
Admin15.07.2021

Encarnación Sastre

Encarnacion nackt Sastre Encarnación Sastre
0 ,c ;clearInterval e ;s.
pale
806
Admin05.09.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Encarnacion nackt Sastre Encarnación Sastre
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 tribe study.
pale
9600
Admin15.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Encarnacion nackt Sastre Encarnación Sastre
MJS has done consulting or advisory roles for Amgen, Merck, Roche, Sanofi and Servier, and received travel, accommodation, and expenses from Amgen, Merck and Roche.
erotica
3209
Admin30.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Encarnacion nackt Sastre FOLFOXIRI plus
The vertical dashed line indicates a HR of 1.
erotica
2906
Admin17.07.2021

Encarnación Sastre

Encarnacion nackt Sastre Encarnación Sastre
15 Hospital General Universitario de Valencia, Medical Oncology Department, Valencia, Spain.
outside
4100